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Abstract
Introduction Response to current therapy of hepatitis C
virus (HCV) is suboptimal. Direct-acting antiviral therapies
(DAA) are expected to improve treatment outcomes.
Additional treatments for HCV will invariably make ther-
apeutic choices and patient management more complex.
We hypothesize that current perceptions regarding the
complexity of DAA therapy will inﬂuence attitudes
towards future use by practitioners who are currently
treating HCV.
Methods An Internet-based survey was sent to 10,082
AASLD and AGA members to determine if they treat HCV
infection, their knowledge of DAA therapies, attitudes
towards current and future HCV treatments, and if they
participated in clinical trials using DAA agents.
Results Out of a total of 1,757 individuals responding to
the survey, 75% treat HCV; 79% were MDs, 67% were
Gastroenterologists, and 24% were Hepatologists. Of the
respondents, 77% indicated they were ‘‘very aware’’ or
‘‘aware’’ of DAA therapies, 20% participated in clinical
trials, and 3% had minimal knowledge of DAA agents.
Comparing treatment ‘‘today’’ versus in the future when
DAAs were available, 85 vs. 81% would treat (p =
0.0054), 6 vs. 10% would refer to an ‘‘HCV expert’’ (p =
0.016), and 1% would refer to an ID specialist. Of
respondents with ‘‘minimal knowledge’’ of DAA, 52%
stated that they would use them in the future.
Conclusions Although the majority of respondents appear
ready to utilize DAA agents in the future, referrals to
‘‘hepatitis C experts’’ will increase. More than half of
respondents with ‘‘minimal knowledge’’ of DAA therapies
also appear to be willing to utilize these compounds,
raising concerns regarding their inappropriate use. Broad
education of healthcare providers to prevent inappropriate
use of these agents will be critical.
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Introduction
Hepatitis C virus (HCV) represents the most common
chronic blood-borne viral infection in the United States [1,
2]. At present, response to currently available therapy
remains suboptimal as a signiﬁcant number of patients fail
to achieve a sustained virologic response to therapy [3–10].
Recent discoveries related to the life cycle and pathobiol-
ogy of HCV have led to the development of novel therapies
that directly inhibit viral replication. These compounds,
characterized as ‘‘speciﬁcally targeted antiviral therapies
against HCV’’ (STAT-C) or ‘‘direct-acting antiviral
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previously treated patients, and preliminary data from these
studies have been encouraging [11–14]. Along with these
encouraging results, these and other publications which
describe experience with DAA agents have documented
the emergence of HCV resistance [15, 16], as well as
signiﬁcant treatment-related adverse events including rash,
gastrointestinal side-effects, and anemia [11–14].
As health care providers with interest and experience in
treating HCV become aware of emerging data using novel
therapeutic agents, we hypothesize that current perceptions
regarding the complexity and side-effects of DAA thera-
pies will inﬂuence decisions regarding the future use of
these agents. To evaluate attitudes regarding the future use
of these agents by individuals who are currently treating
HCV, we sent an Internet-based survey to all United States-
based members of the American Gastroenterology Asso-
ciation (AGA) and American Association for the Study of
Liver Disease (AASLD). Members of these societies were
chosen because they represent both the vast majority of
HCV treaters in the United States, and a population of
clinicians likely to have knowledge of DAA therapies.
Recipients of the survey were queried regarding their pri-
mary professional afﬁliation and focus of practice, attitudes
towards current and future HCV therapy, as well as par-
ticipation in clinical trials using DAA agents. We deter-
mined if any of these parameters affected attitudes related
to current and future treatment decisions regarding HCV.
Methods
This study was reviewed and approved by the institutional
review board at the Albert Einstein College of Medicine/
Monteﬁore Medical Center. The e-mail addresses of the
10,082 US-based members of the AGA and AASLD were
compiled from the 2009 member directories for both
organizations. AGA and AASLD members were selected
to be surveyed as they represent the majority of HCV
treaters in the United States. Prescriber Proﬁler
TM data
provided to the authors by IMS Health Incorporated,
reﬂecting a US-based database of retail pharmacies and
total dispensed prescriptions of Copegus
TM, Intron-A
TM,
Infergen
TM, Pegasys
TM, Peg-Intron
TM, Rebetol
TM, Rebe-
tron
TM, Ribasphere
TM, and Ribavirin
TM indicated that
between December 2008 and November 2009, 177,300
prescriptions were written. Gastroenterologists or Hepa-
tologists wrote approximately 94,000 or 55% of these,
validating our hypothesis that the targeted survey recipients
were a group which treated HCV most frequently. Internal
medicine physicians (11%) and nurse practitioners (8%)
were the next most common prescribers [17]. Using
an Internet-based survey engine (‘‘SurveyMonkey’’
(surveymonkey.com)) a nine-question survey was sent to
each AGA or AASLD member; only one questionnaire was
sent to individuals who are members of both organizations.
If an individual did not respond to the survey, the survey
was re-sent with a second request to complete the survey.
All results were tabulated, and statistical analysis was
performed using Stata version 9.2, Statcorp LP, College
Station, Texas.
Results
Of the 10,082 surveys sent, 8,449 were deliverable. The
most common reasons for inability to deliver a survey
included use of an e-mail ﬁlter or vacation message by the
intended recipient. A total 1,757 individuals responded to
the survey, representing a 21% response rate. A recent
analysis performed by supersurvey.com revealed a mean
response rate of 18% to online surveys of similar question
size and target audience (www.supersurvey.com). The
survey questions and responses appear in Table 1.I fa
respondent stated that they did not treat HCV, their par-
ticipation in the survey ended after question 1.
Of the respondents, 75% (1,320) stated that they treat
HCV, and of these respondents, 79% were MDs, 10% were
physician assistants or nurse practitioners, 8% MD-PhDs,
2% DO, and 1% PhD. Of the respondents, 32% graduated
within the last 10 years, 25% 11–20 years ago, 21%
21–30 years ago, and 12% greater than 30 years ago.
Whenanalyzingresultsbasedonfocusofpractice,67%of
respondents stated that gastroenterology was the primary
focusoftheirclinicalpractice,24%selectedhepatologyand/
orlivertransplantation,2%infectiousdisease,and7%stated
‘‘other’’ as the primary focus of their practice. The ‘‘other’’
respondentsincludedprimarycaredoctors,surgeons,aswell
as Gastroenterologists who considered hepato-biliary dis-
ease,oncology,orpancreaticdiseasetheirprimaryspecialty.
Forty-six percent of the respondents were in a private prac-
tice not associated with a medical school, 42% at a medical
school or hospital associated with a medical school, 8% in a
private practice associated with a medical school, and the
remaining 4% of respondents practiced in a multispecialty
grouppractice,VeteransAdministrationhospital,orhospital
not associated with a medical school.
Professional afﬁliations were assessed; 55% of respon-
dents considered the American Gastroenterological Asso-
ciation (AGA) their primary professional afﬁliation, 26%
the American Association for the Study of Liver Disease
(AASLD), 9% the American Society for Gastrointestinal
Endoscopy (ASGE), and 10% ‘‘other’’ including the
American College of Gastroenterology (ACG), American
Medical Association (AMA), and the American Society for
Transplantation (AST).
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presented with an HCV-infected patient ‘‘today,’’ 85% of
the respondents would treat them, 6% would refer them to
a ‘‘hepatitis C expert,’’ 4% would refer them to a physician
extender (PA, NP, or specially trained nurse) in their
practice, 4% would refer to another MD in their practice,
and 1% would refer them to an infectious disease spe-
cialist. Related to future therapies for HCV including
DAAs in combination with interferon and ribavirin, 77%
of the respondents were ‘‘aware’’ or ‘‘very aware’’ of this
concept but had not participated in any clinical trials using
DAA agents, 20% were ‘‘very aware’’ and had experience
using these agents in clinical trials, and 3% had ‘‘minimal
knowledge’’ of DAA agents.
When queried regarding treatment approaches if a DAA
agent were available ‘‘today,’’ 81% of respondents would
evaluate and treat the patient, 10% would refer the patient
to a ‘‘hepatitis C expert,’’ 5% would refer the patient to
another physician in their group, and 4% would refer the
patient to a physician extender (PA, NP, or specially
trained nurse) in their practice. Less than 1% of respon-
dents reported that they would refer the patient to an
infectious disease specialist.
Analysis of survey results (Table 2):
Overall, a signiﬁcant number of respondents who treat
HCV today with currently available therapies indicated that
they would not prescribe DAA therapies when they became
available; 85% of respondents to the survey would evaluate
Table 1 Responses to
questions by respondents who
treat HCV
Highest level of education 79% MD
10% PA
8% MD-PhDs
2% DO
1% PhD
Year of graduation from the
last school you attended
32% within the last 10 years
25% 11–20 years ago
21% 21–30 years ago
12%[30 years ago
Primary focus of practice 67% Gastroenterology
24% Hepatology and/or liver transplantation
2% Infectious disease
7% ‘‘other’’
Location of primary practice 46% private practice not assoc with a medical school
42% medical school/hospital assoc with a medical school
8% private practice associated with a medical school
4% ‘‘other’’
Primary professional afﬁliation 55% AGA
26% AASLD
10% ‘‘other’’
9% ASGE
‘‘If I saw a patient with HCV today’’… 85% would treat
6% would refer them to a ‘‘hepatitis C expert’’
4% would refer them to NP, PA in their practice
4% would refer to another MD in their practice
1% would refer them to an Infectious Disease specialist.
Awareness of DAA therapy 77% ‘‘aware’’ or ‘‘very aware’’ without participation
in any clinical trials
20% were ‘‘very aware’’ and had experience using these
agents in clinical trials
3% had ‘‘minimal knowledge’’ of STAT-C agents
If DAA therapies were available today 81% would evaluate and treat the patient
10% would refer to a ‘‘Hepatitis C expert’’
5% would refer to another physician in their group
4% would refer the patient to NP, PA in their practice
\1% would refer to an infectious disease specialist
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when DAA agents became available (p = 0.0054). Simi-
larly, more respondents indicated that they would refer
their patients to a ‘‘hepatitis C specialist’’ after DAA agents
became available (6% current, 10% after DAA availability
(p = 0.016).
Signiﬁcant differences existed based on primary pro-
fessional afﬁliation in attitudes and experience of survey
respondents related to present and future HCV therapy.
Ninety-one percent of respondents who considered the
AASLD their primary afﬁliation compared to 84% of AGA
members would treat their HCV-infected patient today
(p = 0.002), 48% of AASLD members versus 9% of AGA
members participated in clinical trials with a DAA agent
(p = 0001), and 91% of AASLD members versus 79% of
AGA members would use a DAA agent to treat their HCV-
infected patient in the future (p = 0.001). A greater per-
centage of AGA members (12%) stated that they would
refer their patient to an ‘‘HCV expert’’ when DAA agents
became available compared to AASLD members (3%)
(p = 0.001). When analyzing attitudes related to current
and future therapy of HCV based on focus of clinical
practice, a comparison of Hepatologists/liver transplanta-
tion physicians to Gastroenterologists revealed that 93%
versus 86% would treat their HCV-infected patient today
(p = 0.0034), 48% compared to 8% participated in clinical
trials using DAA agents (p = 0.001), 90% versus 81%
would treat their patient with a DAA agent (p = 0.001),
and 1% versus 8% would refer their patient to an
‘‘HCV expert’’ when DAA therapies became available
(p = 0.001).
Practice type was also associated with differences in
attitudes related to current and future therapy of HCV.
Comparison of respondents in private practice versus those
who practiced at a medical school or hospital associated
with a medical school revealed that respectively, 91%
versus 81% would treat their HCV-infected patient today
(p = 0.001), 9% versus 30% participated in a clinical trial
with a DAA agent (p = 0.001), 89% versus 75% would use
DAA therapies when they became available (p = 0.001),
and 12% compared to 15% would refer to an ‘‘HCV
expert’’ when DAA therapies became available (P = NS).
Current awareness and participation in clinical trials
with DAA agents inﬂuenced attitudes regarding future use
of these therapies, as 90% of respondents who participated
in clinical trials with DAAs, 81% of those who were ‘‘very
aware’’ or ‘‘aware’’ of DAA agents but did not participate
in clinical trials, and 59% of those with minimal knowl-
edge of DAA therapies would prescribe these agents in the
future (p = 0.0001 clinical trial participant/very aware or
aware of DAA agents vs. minimal knowledge). Respon-
dents with ‘‘minimal knowledge’’ of DAA agents also
reported that when these compounds were available in the
future, 25% would refer their HCV-infected patient to a
PA, NP, or other MD in their practice, 22% would refer to
an ‘‘HCV expert,’’ and 1% would refer to an ID specialist.
Respondents who reported ‘‘minimal knowledge of DAA
agents’’ were more likely to consider the AMA their pri-
mary professional organization (20 vs. 1% AGA/AASLD
(p = 0.001)), or be in a private practice not associated with
a medical school (83 vs. 17% practice or hospital associ-
ated with a medical school p = 0.0001).
Discussion
Emerging data suggest that direct-acting antiviral therapies
against HCV (DAA) will provide improved response rates
when given in combination with currently available ther-
apies. The enthusiasm for these new treatments must be
tempered by realistic concerns including side-effects as
well as the threat of viral resistance induced by these
agents. We hypothesized that concern regarding these
issues might affect attitudes of future use of DAA therapies
by health care providers who currently treat HCV. The goal
of the current study was to query a group of experienced
Table 2 Current and future therapy, and future referral to an HCV specialist
Respondent characteristic Would treat
HCV today
Would treat with
DAA in the future
Future referral to
HCV specialist
p value
Overall 85 (%) 81 (%) 10 (%) 0.0054
AASLD member
A91
B91
C3
A0.002
B,C0.001 AGA member
A84
B79
C12
Hepatologist
D93
E90
F1
D.0034
E,F0.001 Gastroenterologist
D86
E81
F8
Private practice
G91
H89
I12
G,H0.001
INS Academic practice
G81
H75
I15
Participated in DAA Clinical trial
J91
K90
L4
J,K,L0.0001
Minimal knowledge of DAA
J59
K52
L22
The p value related to the statistical signiﬁcance of the comparisons of groups A to A, B to B, C to C, etc are reported
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attitudes regarding current and future treatment of HCV
and correlate these responses related to focus of clinical
practice, academic versus private practice, professional
afﬁliation, and experience with DAA agents in clinical
trials. US-based members of the AGA and AASLD were
targeted for the survey as they represent the majority of
HCV treaters in the US and a group most likely to have
knowledge of DAA therapy. This manuscript represents the
ﬁrst description of attitudes regarding future use of DAA
agents in a large group of experienced HCV treaters.
Based on responses to this survey, although the majority
of current HCV treaters would prescribe a DAA agent, a
signiﬁcant number of respondents who treat HCV today
(85%) would not initiate therapy when these agents became
available in the future (81%). The decreased use of DAA
therapies may be offset somewhat by an increase in
referrals to a more experienced HCV treater, as more
respondents would refer their patients to a ‘‘hepatitis C
expert’’ after DAA agents became available in the future
compared to referring patients if they were diagnosed with
HCV today (10% versus 6%). Not surprisingly, future use
of DAA therapy appears to be signiﬁcant in treaters who
identify themselves as Hepatologists, and those with
experience using these agents in clinical trials. Moreover,
direct clinical experience with DAAs did not appear to
dampen the enthusiasm for future use of these agents, as
90% of respondents who participated in clinical trials with
a DAA agent would utilize these agents to treat an HCV-
infected patient when these agents became available.
We hypothesized that as infectious disease specialists
have extensive experience prescribing oral antiviral agents
for HIV, referrals to these providers would increase when
DAA agents became available for HCV. Our hypothesis
was clearly inaccurate as respondents to the survey were
unlikely to refer their HCV-infected patients to an infec-
tious disease specialist when faced with an HCV-infected
patient today (1%) and when DAA agents were available in
the future (0.8%). This trend was maintained even in
respondents with minimal knowledge of DAA agents.
Finally, a concerning observation was identiﬁed when
assessing responses to the survey stratiﬁed by past experi-
ence with DAA therapy. Although a signiﬁcant percentage
of respondents who participated in clinical trials with a
DAA (90%) or who were ‘‘aware or very aware’’ of these
agents but did not participate in a clinical trial (81%) would
use these agents in the future, more than half of respondents
(52%) who reported minimal knowledge of DAA agents
stated that they would also use them in the future. Although
providers with minimal knowledge of DAA agents repre-
sented a small percentage of respondents to the survey,
concern exists regarding the inappropriate use of DAAs
in the future including inexperience with side-effect
management, and lack of recognition of both treatment
failure as well as the emergence of viral resistance [11–16].
It is therefore apparent to the authors of this manuscript that
extensive education of all future prescribers of DAA agents
will be required to ensure successful use of these therapies.
There are limitations of this study that are unfortunately
shared by other surveys utilizing similar data collection and
analyses techniques. Any Internet-based survey is limited
by response rate, which is affected both by the ability to
deliver the survey and the willingness of the survey reci-
pient to accurately respond to the queries posed to them.
Although 21% of recipients of the survey responded, it is
possible that the identiﬁed results would have been dif-
ferent if more individuals completed the survey. Unfortu-
nately, the large volume of unsolicited e-mail has induced
the use of blockers and ﬁlters, thus potentially limiting the
response rates to the survey. However, we believe that
these limitations were balanced by several strengths
including the overall brevity of the survey (nine questions)
increasing the likelihood that those who received and
opened the survey fully completed it, and by the target
audience which represented a signiﬁcant number of current
HCV treaters with the highest likelihood of having
knowledge regarding DAA agents.
In summary, the responses to this Internet-based survey
of more than 1,000 current HCV treaters indicated that
although the majority of respondents appear ready to utilize
DAA agents in the future, referrals to ‘‘hepatitis C experts’’
will increase when these agents become available. In
addition, future referrals to ID specialists appear to be
limited. Finally, as more than half of respondents to the
survey with ‘‘minimal knowledge’’ of DAA therapies also
appear to be willing to utilize these compounds in the
future, signiﬁcant provider education will be required to
minimize inappropriate use of these agents.
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Appendix: HCV Survey
Question 1. Do you treat patients with hepatitis C? Yes/No
Question 2. What is your highest level of education?
s MD
s DO
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123s PhD
s MD/PhD
s PA/NP
Question 3: What year did you graduate medical school (or
osteopathic or graduate school)?
Question 4: What is the primary focus of your clinical
practice? (please select one)
s General gastroenterology
s Hepatology
s Hepatology and liver transplantation
s Primary care
s Infectious disease
s Research
s Other
Question 5: What is the location of your primary practice?
s Medical school or hospital associated with a medical
school
s Hospital not associated with a medical school
s V.A.
s Private practice associated with a medical school
s Private practice not associated with a medical school
s Other
Question 6: What is your primary professional afﬁliation?
s AASLD
s AGA
s AMA
s ASGE
s Other
Question 7: If I saw a patient with hepatitis C today I would
(choose one answer):
s Evaluate and treat the patient
s Refer the patient to a hepatitis C expert
s Refer the patient to another physician in my practice
s Refer the patient to an RN,PA or other physician
extender in my practice
s Refer the patient to an infectious disease specialist
Question 8: In the near future, hepatitis C therapy will
likely include an interferon-like agent, a medication like
ribavirin and direct-acting antiviral therapies such as pro-
tease and polymerase inhibitors. How aware are you of this
concept?
s Very aware, have participated in trials using these
new therapies
s Very aware, have not participated in trials using these
new therapies
s Aware
s Minimal knowledge
Question 9: When direct-acting antiviral therapies (e.g.,
protease and polymerase inhibitors) become available and
you see a patient who would require them you would:
s Evaluate and treat the patient
s Refer the patient to a hepatitis C expert
s Refer the patient to another physician in my practice
s Refer the patient to an RN,PA or other physician
extender in my practice
s Refer the patient to an infectious disease specialist
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